Tools & Resources / Webinars / Webinar: Cytotoxicity Bioassays – Measuring Antibody-Mediated Direct Cell Death
Tools & Resources

Webinar: Cytotoxicity Bioassays – Measuring Antibody-Mediated Direct Cell Death

<June 2022>
SunMonTueWedThuFriSat
29
 
30
 
31
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
Webinar: Cytotoxicity Bioassays – Mea...
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 

Webinar: Cytotoxicity Bioassays – Measuring Antibody-Mediated Direct Cell Death

 

During the development of antibody therapeutics, regulators now require assays to evaluate Fc effector function demonstrating immune cell-mediated killing via ADCC and ADCP rather than a surrogate endpoint for antibody engagement of antigen on target cells. Eurofins DiscoverX’s KILR® cytotoxicity assay platform specifically measures antibody-mediated killing of antigen-expressing target cells in co-culture with effector cells. This platform is now available as ready-to-use bioassays for several tumor models, including Raji and Daudi, for use in screening and lot-release applications. These bioassays are qualified with Rituximab and demonstrate high repeatability and inter-analyst performance.


Register Now
Event capacity: N/A
Event location:
Event date: 6/16/2022, 8:00 AM - 8:00 PM
Event Date ▼ Event Name PDF Link Webinar Link
June 16, 2022 Webinar: Cytotoxicity Bioassays – Measuring Antibody-Mediated Direct Cell Death
February 23, 2022 Webinar: Unlocking Orphan GPCRs with an Innovative Forward Trafficking Approach – 45 min. + 30 min. Q&A
July 28, 2021 Webinar: Automating Functional Cell-based Bioassays: Assay Reproducibility and Performance for Potency Testing Programs - 45 min.
March 30, 2021 Webinar: Novel Small Molecule Inhibitors of Oncogenic SHP2 Variants Characterized by Cellular Target Engagement - 45 min.
October 28, 2020 Webinar: Accelerating COVID-19 Drug Discovery: Qualified Cell-Based Assays for Proinflammatory Cytokines - 45 min.
June 17, 2020 Webinar: Simple Signaling Reporter Assays – Easily Quantify Activation & Inhibition of Cellular Pathways - 30 min.
February 26, 2020 Webinar: Protein Degradation (PROTACs/CRISPR) Assays - 60 min.
October 9, 2019 Webinar: Establishing Qualified Bioassays for Checkpoint Receptors to Implement in QC Lot Release: Case Studies on PD-1 and SIRPα - 60 min.
May 9, 2018 Webinar: Accelerate Biologics and Biosimilars Development: Case Studies Implementing Robust and Simple Potency Bioassays - 60 min.
November 1, 2017 Webinar: How to Accelerate Your Biotherapeutic Development with Cell-Based Assay Services - 40 min.

What will be covered?

  • How PathHunter services save development time compared to in-house assays
  • Screening and profiling biologics with highly specific and sensitive assays that produce robust and reproducible results
  • Example data from marketed drugs, like Pembrolizumab and Nivolumab, using these cell-based assays
September 20, 2017 Webinar: Create Your Own Cell-Based Assays to Study Receptor Tyrosine Kinase Function - 30 min.

What will be covered?

  • RTK biology and drug discovery importance
  • Tools needed to create your own RTK cell lines and assays
  • Experimental design and workflows
  • Applications of RTK and related cell-based assays
April 19, 2017 Webinar: Combining Target-Based and Phenotypic Discovery Assays for Drug Repurposing - 40 min.

What will be covered?

  • Using phenotypic profiling to characterize clinically successful drugs for a given indication
  • Combining target-based and phenotypic data to prioritize drugs for repurposing
  • Understanding how multi-targeted kinases can be pivoted towards new indications
September 30, 2016 Webinar: Immuno-Oncology Drug Development: Profiling Immunomodulatory Biologics and Compounds in Human Primary Cell-Based Oncology Models - 60 min.

What will be covered?

  • Overview of the BioMAP® immuno-oncology/oncology systems
  • Information BioMAP iOnc studies provide
  • Host stromal/vascular - tumor microenvironment biology
  • Case studies of profiling Ab therapies (anti-PD-1, anti-CTLA-4, etc.) and preclinical compounds
May 25, 2016 Webinar: A Phenotypic Platform for Characterization of Drug Safety Mechanisms in Human Primary Cell Disease Models - 40 min.

What will be covered?

  • How to maximize knowledge of your compounds using the BioMAP® Diversity PLUS™ panel of human primary cells systems
  • How to understand mechanism classification analysis and toxicity signatures
  • A case study on discovery of a mechanism-based novel signature for skin irritation